Oric update covers rinzimetostat Phase III safety and enozertinib ESMO plans

Oric said rinzimetostat is in Phase III for prostate cancer and that it will continue development. For lung cancer with brain metastases, Oric said enozertinib data will be presented at ESMO as it outlines partner plans and funding.